XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenues:        
Revenues $ 81,000 $ 10,000 $ 81,000 $ 43,000
Operating expenses:        
Cost of sales 64,000 64,000
Research and development 5,000 950,000 895,000 5,775,000
General and administrative 1,004,000 1,237,000 6,467,000 4,444,000
Total operating expenses 1,073,000 2,187,000 7,426,000 10,219,000
Operating loss (992,000) (2,177,000) (7,345,000) (10,176,000)
Other expense:        
Foreign exchange gains (losses) (14,000) 2,000 (25,000) 6,000
Interest income (expense) 9,000 8,000 17,000 (18,000)
Gain on deconsolidation of subsidiary 4,947,000
Other income, net 9,000 21,000 52,000
Total other income, net 4,000 10,000 4,960,000 40,000
Loss before taxes (988,000) (2,167,000) (2,385,000) (10,136,000)
Income tax benefit (charge) 210,000 (2,000) 1,976,000
Net loss (988,000) (1,957,000) (2,387,000) (8,160,000)
Dividend on convertible exchangeable preferred shares (21,000) (41,000)
Deemed dividend on warrant exchange (1,494,000) (1,494,000)
Net loss applicable to common shareholders $ (2,503,000) $ (1,957,000) $ (3,922,000) $ (8,160,000)
Basic and diluted earnings per common share:        
Net loss per share - basic (common shareholders) $ (1.31) $ (43.80) $ (2.86) $ (490.01)
Net loss per share, diluted $ (1.31) $ (43.80) $ (2.86) $ (490.01)
Weighted average common shares outstanding - basic 1,912,495 44,681 1,368,954 16,646
Weighted average common shares outstanding - diluted 1,912,495 44,681 1,368,954 16,646
Product Revenue Fire Safety [Member]        
Revenues:        
Revenues $ 81,000 $ 81,000
Clinical Trial Supply [Member]        
Revenues:        
Revenues $ 10,000 $ 43,000